In late June, CureVac published final data showing that its vaccine had demonstrated efficacy of 48% against Covid-19. "CureVac Shares Fall Premarket on Termination of Vaccine Contracts With Wacker Chemie, Celonic -- 2nd Update," at 1314 GMT Sept. 14, cited interim data from mid-June which showed the vaccine demonstrating a 47% efficacy.

(END) Dow Jones Newswires

09-15-21 0453ET